Pronota, Molecuence Partner on Stroke Biomarker Deal

Pronota will use its MASStermind platform for the discovery stage of the deal, and its MASSterclass technology for the verification work.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.